Alsempharma SA
2.8 FTEThe score of Alsempharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets 0 % Headcount (avg FTE) -10 %
Accounts of the company itself (not consolidated).
The full file covers 11 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Alsempharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −47,740 € | ||||
| Equity | −66,946 € | ||||
| Cash | 28,262 € | ||||
| EBITDA | −38,446 € | ||||
| Total assets | 336,894 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Jul 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 09 Aug 2024
- Year ended 31 Dec 2022filed on 25 Aug 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
Alsempharma's financial analysis
- Solvency-19.9%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Alsempharma
Alsempharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0460.144.937
- VAT number
- BE0460144937
- Peppol
- Registered · 0208:0460144937 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 03 Mar 1997
- Registered office
- 1652 Beersel
- Size
- Micro · 2.8 FTE
- Latest accounts
- 2025 · filed on 28 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Alsempharma (SA) has been based in Beersel since 1997, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 47,740 € and equity of −66,946 €; its revenue is not published. With 2.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -19.9%, below the median of its sector (44.2%).
Companies similar to Alsempharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek VAN Reeth - Deprost Retail sale of pharmaceutical products Antwerp · balance sheet 336,788 €
- Sogephar Retail sale of pharmaceutical products Ixelles · balance sheet 337,204 €
- Phardec Retail sale of pharmaceutical products Koekelberg · balance sheet 335,635 €
- Pharmaline Retail sale of pharmaceutical products Courcelles · balance sheet 339,554 €
- Nathypharm Retail sale of pharmaceutical products Andenne · balance sheet 340,634 €
- Apoteek DE Smedt Retail sale of pharmaceutical products Asse · balance sheet 343,684 €
- Pharma pour Tous Namur Retail sale of pharmaceutical products Namur · balance sheet 340,936 €
- Geassocieerde Apotheek Ekeren Retail sale of pharmaceutical products Antwerp · balance sheet 331,202 €
Frequently asked questions about Alsempharma
What is the revenue of Alsempharma?
Alsempharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Alsempharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0460144937 for Alsempharma, if the company is VAT-registered. Its company number (CBE) is 0460.144.937.
Where is the registered office of Alsempharma?
According to the CBE register, the registered office of Alsempharma is in 1652 Beersel.
What is the equity of Alsempharma?
At the close of the 2025 financial year, the equity of Alsempharma amounts to -66,946 €, a solvency of -19.9% of total assets.
How many people work at Alsempharma?
2.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Alsempharma?
The register lists 3 active mandates at Alsempharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Alsempharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →